LBT Innovations Limited (ASX:LBT) Managing Director & CEO Brent Barnes presents on LBT's automated plate reading device for use in laboratories, regulatory clearance in the US and the size of the market opportunity at FNN's Investor Event.
Key points: - LBT Innovations (ASX:LBT) has an FDA cleared artificial intelligence platform automating manual healthcare processes
- Commercial launch underway in Australia, Europe and the US
- 1st sale completed - St. Vincent’s Hospital, Melb
- FDA cleared - 10,000 patient clinical study
- Attractive revenue model - upfront + annual fees
- Cost and efficiency gains for Pathology labs 3 times faster than manual reading
- Addressable market 2H 2019- 2,000 labs
For more, watch Managing Director & CEO Brent Barnes present.
